Calcium folinate (levoleucovorin)-Kimia
Product Description
EXAMON Handelsges.m.b.H.

-
AT
-
2024On CPHI since
Categories
Specifications
EXAMON Handelsges.m.b.H.

-
AT
-
2024On CPHI since
More Products from EXAMON Handelsges.m.b.H. (32)
-
Product Gefitinib-GEFISA®
• Used for non-small cell lung cancer (NSCLC) as first-line therapy. Targets EGFR mutations to inhibit tumor growth. • An EGFR tyrosine kinase inhibition which interrupts receptor signaling to limit tumor cell proliferation. • Robust clinical studies confirm benefits in non-small cell lung and pan... -
Product Pazopanib-PAZOTRI®
• Inhibits multiple receptor tyrosine kinases, including VEGF, PDGF, and c-kit, to reduce tumor angiogenesis and growth. • Demonstrated clinical effectiveness in advanced renal cell carcinoma (second-line) and soft tissue sarcoma (second-line) through robust trials. • Administered orally, offering ... -
Product Sunitinib-KITENT®
• Multi-targeted tyrosine kinase inhibitor that blocks VEGF and PDGF receptors to hinder tumor angiogenesis and cell proliferation • Proven efficacy in advanced renal cell carcinoma (second-line), gastrointestinal stromal tumors (first-line), and pancreatic neuroendocrine tumors (second-line) • Administ... -
Product Fampridine(Dalfampridine)
• Fampridine acts by blocking voltage-dependent potassium channels, thereby enhancing conduction in demyelinated nerve fibers. • Robust clinical trials have confirmed its ability to improve walking speed and overall mobility in multiple sclerosis patients. • Delivered in tablet form, ensuring convenient... -
Product Azacitidine-Kimia
• Incorporates into nucleic acids to induce DNA hypomethylation. • Clinically validated for myelodysplastic syndromes and AML. • Flexible administration via subcutaneous injection or IV infusion. • Established safety profile confirmed in rigorous clinical trials. • Demonstrated improvements in surviva... -
Product Bortezomib-Kimia
• Inhibits the 26S proteasome, triggering targeted tumor cell apoptosis. • Clinically indicated for multiple myeloma and mantle cell lymphoma. • Offers flexible IV and subcutaneous administration options. • Demonstrated improvements in survival and quality of life. • Established, well-characterized sa... -
Product Carboplatin-Kimia
• Disrupts tumor DNA through crosslink formation to impede cell replication. • Widely validated in the treatment of various solid malignancies, including ovarian and lung cancers. • Administered via infusion to integrate seamlessly into contemporary oncology protocols. • Exhibits manageable adverse eff... -
Product Cisplatin-Kimia
• Facilitates DNA crosslinking to inhibit replication and promote cancer cell apoptosis. • Demonstrates robust efficacy in various solid tumors, including testicular, ovarian, and bladder cancers. • Delivered via infusion, aligning with established oncology treatment protocols. • Often paired with othe... -
Product Docetaxel-Kimia
• A potent taxane agent which stabilizes microtubules to disrupt cell division and promote apoptosis in malignant cells. • Demonstrated efficacy across various cancers including breast, lung, and prostate. • Seamlessly integrated into standard oncology treatment protocols. • Adverse effects are managea... -
Product Doxorubicin-Kimia
• An anthracycline mechanism which intercalates into DNA and inhibits topoisomerase II, promoting the generation of free radicals that induce tumor cell death. • Demonstrates a longstanding, evidence-based role in treating breast cancer, lymphomas, sarcomas, and other malignancies. • Delivered via IV in... -
Product Epirubicin-Kimia
• An anthracycline derivative which intercalates into DNA and inhibits topoisomerase II, disrupting cancer cell replication. • Demonstrated success in the treatment of breast and other solid tumors through extensive clinical trials. • Delivered via infusion, integrating smoothly into established chemoth... -
Product Gemcitabine-Kimia
• Gemcitabine functions as a nucleoside analog that, once activated, impedes DNA synthesis and triggers tumor cell death. • Its therapeutic use is well-established in treating a range of malignancies, including pancreatic, lung, and breast cancers. • The drug is administered through intravenous infusion...
Frequently Viewed Together
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance